The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•8 April 2026•

1 min read

Arcutis Stock Surges 65% as Director Executes Pre-Planned Share Sale

Key Facts

1Arcutis Biotherapeutics stock rose by 65%.

2Director Howard G. sold 10,000 shares for a total transaction value of $239,000.

3The sale was executed under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics (ARQT) shares experienced a significant rally, climbing 65% in recent trading sessions. Amid this surge, company director Howard G. sold 10,000 shares of the biotech firm. The transaction, valued at approximately $239,000, was executed under a pre-arranged 10b5-1 trading plan. These regulatory plans allow insiders to schedule stock sales in advance to mitigate concerns regarding insider trading. While large insider sales can sometimes signal caution, the automated nature of this trade suggests it was independent of the recent price action. Investors continue to monitor the company's performance following this massive appreciation in its stock price.